Stock SOBI SWEDISH ORPHAN BIOVITRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 03:57:23 2024-04-29 am EDT 		5-day change 1st Jan Change
278 SEK -1.07% Intraday chart for Swedish Orphan Biovitrum AB +5.10% +3.45%
Apr. 26 Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug MT
Apr. 26 Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 45,437 48,345 54,631 63,845 90,680 95,503 - -
Enterprise Value (EV) 1 61,161 62,093 64,131 71,251 109,945 109,163 104,968 97,644
P/E ratio 13.8 x 15.2 x 20.5 x 24.4 x 36.1 x 28.1 x 19.8 x 15.2 x
Yield - - - - - - - -
Capitalization / Revenue 3.19 x 3.17 x 3.52 x 3.4 x 4.1 x 3.87 x 3.52 x 3.13 x
EV / Revenue 4.29 x 4.07 x 4.13 x 3.79 x 4.97 x 4.42 x 3.87 x 3.2 x
EV / EBITDA 9.99 x 9.09 x 11.2 x 10.5 x 14.3 x 12.3 x 9.96 x 7.86 x
EV / FCF -3.39 x 49.7 x 12.6 x 15.5 x 27.1 x 17.4 x 14.8 x 11.4 x
FCF Yield -29.5% 2.01% 7.96% 6.45% 3.7% 5.76% 6.78% 8.79%
Price to Book 2.74 x 2.42 x 2.46 x 2.52 x 2.79 x 2.58 x 2.31 x 2.02 x
Nbr of stocks (in thousands) 294,091 291,059 295,145 295,991 339,627 339,868 - -
Reference price 2 154.5 166.1 185.1 215.7 267.0 281.0 281.0 281.0
Announcement Date 2/13/20 2/18/21 2/10/22 2/8/23 2/8/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 14,248 15,261 15,529 18,790 22,123 24,709 27,134 30,513
EBITDA 1 6,121 6,830 5,740 6,758 7,676 8,904 10,540 12,419
EBIT 1 4,533 4,818 3,733 4,488 4,485 5,335 7,196 9,189
Operating Margin 31.81% 31.57% 24.04% 23.89% 20.27% 21.59% 26.52% 30.12%
Earnings before Tax (EBT) 1 4,247 4,217 3,295 3,321 2,954 4,236 6,101 8,164
Net income 1 3,304 3,245 2,679 2,638 2,409 3,391 4,895 6,550
Net margin 23.19% 21.26% 17.25% 14.04% 10.89% 13.72% 18.04% 21.47%
EPS 2 11.22 10.90 9.030 8.840 7.390 10.00 14.16 18.51
Free Cash Flow 1 -18,051 1,250 5,103 4,593 4,063 6,288 7,115 8,579
FCF margin -126.69% 8.19% 32.86% 24.44% 18.37% 25.45% 26.22% 28.12%
FCF Conversion (EBITDA) - 18.3% 88.9% 67.96% 52.93% 70.62% 67.5% 69.08%
FCF Conversion (Net income) - 38.52% 190.48% 174.11% 168.66% 185.43% 145.34% 130.97%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/18/21 2/10/22 2/8/23 2/8/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,896 4,925 3,876 3,999 5,991 5,239 4,872 5,168 6,844 6,256 5,164 6,090 7,280 6,570 6,146
EBITDA 1 2,061 1,461 997 1,278 2,493 2,159 1,286 1,585 2,645 2,377 1,398 2,040 3,075 2,713 2,476
EBIT 1 1,525 1,437 423 699 1,916 1,495 413 547 1,691 1,468 564 1,399 2,134 1,774 1,537
Operating Margin 31.15% 29.18% 10.91% 17.48% 31.98% 28.54% 8.48% 10.58% 24.71% 23.47% 10.92% 22.97% 29.31% 27% 25.01%
Earnings before Tax (EBT) 1 1,423 674 317 564 1,766 1,325 275 116 1,237 982 207.6 878 1,984 1,589 1,384
Net income 1 1,241 543 258 451 1,386 1,067 222 94 1,026 800 163.3 694 1,568 1,256 1,093
Net margin 25.35% 11.03% 6.66% 11.28% 23.13% 20.37% 4.56% 1.82% 14.99% 12.79% 3.16% 11.39% 21.54% 19.12% 17.78%
EPS 2 4.180 1.830 0.8600 1.510 4.640 3.560 0.7400 0.3000 2.990 2.330 0.4550 2.050 4.745 3.550 3.090
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/10/22 4/28/22 7/19/22 10/27/22 2/8/23 4/27/23 7/18/23 10/30/23 2/8/24 4/25/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,724 13,748 9,500 7,406 19,265 13,661 9,465 2,141
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.569 x 2.013 x 1.655 x 1.096 x 2.51 x 1.534 x 0.898 x 0.1724 x
Free Cash Flow 1 -18,051 1,250 5,103 4,593 4,063 6,288 7,115 8,579
ROE (net income / shareholders' equity) 25.4% 17.5% 12.3% 10.6% 7.98% 9.64% 12.2% 14.1%
ROA (Net income/ Total Assets) 10.5% 6.91% 5.53% 5.22% 3.81% 4.52% 6.29% 7.12%
Assets 1 31,422 46,970 48,472 50,579 63,228 75,066 77,841 91,945
Book Value Per Share 2 56.40 68.50 75.10 85.60 95.60 109.0 122.0 139.0
Cash Flow per Share 2 12.30 17.50 18.40 15.80 13.70 18.90 22.00 28.10
Capex 1 37 41 47 72 407 657 586 729
Capex / Sales 0.26% 0.27% 0.3% 0.38% 1.84% 2.66% 2.16% 2.39%
Announcement Date 2/13/20 2/18/21 2/10/22 2/8/23 2/8/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Swedish Orphan Biovitrum AB

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
281 SEK
Average target price
317.2 SEK
Spread / Average Target
+12.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.45% 8.71B
CSL LIMITED Stock CSL Limited
-4.06% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+55.96% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-6.90% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. Financials Swedish Orphan Biovitrum AB